Improving Vaccine Counseling Skills Among Residents Using Educational Modules and Standardized Patient Encounters
Conditions: Vaccine Refusal; Vaccine-Preventable Diseases; Physician-Patient Relations Interventions: Other: Immersive resident education; Other: Standardized patient (SP) encounter Sponsors: William Beaumont Hospitals; Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 9, 2023 Category: Research Source Type: clinical trials
Don't be Late! Postponing Cognitive Decline and Preventing Early Unemployment in People With Multiple Sclerosis
Conditions: Multiple Sclerosis Interventions: Behavioral: Strenghtening the brain; Behavioral: Strengthening the mind Sponsors: Amsterdam UMC, location VUmc; Universiteit Leiden; Personal Fitness Nederland; MS Vereniging Nederland; Merck BV; Genzyme, a Sanofi Company; MS Sherpa Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 5, 2023 Category: Research Source Type: clinical trials
Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients
Conditions: Cytomegalovirus Infections; Transplant-Related Disorder Interventions: Drug: Letermovir 480 MG [Prevymis] Sponsors: University of Pennsylvania; Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 4, 2023 Category: Research Source Type: clinical trials
CAE for Poorly Adherent Individuals With Schizophrenia
Conditions: Schizophrenia Interventions: Behavioral: Customized Adherence Enhancement for Schizophrenia (CAE-S); Other: Enhanced Treatment as Usual (eTAU) Sponsors: Martha Sajatovic; Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 29, 2023 Category: Research Source Type: clinical trials
Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX)
Conditions: Head and Neck Cancer Interventions: Drug: Xevinapant; Drug: Cisplatin; Radiation: intensity-modulated radiation therapy (IMRT) Sponsors: EMD Serono Research& Development Institute, Inc.; Merck KGaA, Darmstadt, Germany Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 27, 2023 Category: Research Source Type: clinical trials
Efficacy of Letermovir in Preventing Cytomegalovirus (CMV) Infection in Lung Transplant Recipients vs. Valganciclovir.
Conditions: Infections, Cytomegalovirus Interventions: Drug: Letermovir 240 mg Oral Tablet Sponsors: Maim ónides Biomedical Research Institute of Córdoba; MERCK SHARP& DOHME DE ESPA ÑA S.A. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 27, 2023 Category: Research Source Type: clinical trials
An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimester in Finland and Sweden
Conditions: Multiple Sclerosis (MS) Interventions: Drug: Avonex (IFN β-1-a, Biogen Netherlands B.V); Drug: Rebif (IFNβ-1-a, Merck Europe B.V.); Drug: Extavia (IFNβ-1-b, Novartis Europharm Limited); Drug: Betaseron (IFN-β-1-b, BAY86-5046, Bayer AG); Drug: Plegridy (Peg IFNβ-1-a, Biogen Netherlands B.V); Drug: MS disease modifying drugs (MSDMDs) Sponsors: Bayer; Biogen Netherlands B.V; Novartis Europharm Limited; Merck Europe B.V. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 26, 2023 Category: Research Source Type: clinical trials
A Study of Efinopegdutide in Participants With Hepatic Impairment (MK-6024-014)
Conditions: Non-alcoholic Steatohepatitis; Hepatic Impairment Interventions: Drug: Efinopegdutide Sponsors: Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 25, 2023 Category: Research Source Type: clinical trials
A Study to Evaluate Efficacy and Safety of MK-7240 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)
Conditions: Ulcerative Colitis Interventions: Drug: IV MK-7240; Drug: IV Placebo; Drug: SC MK-7240; Drug: SC Placebo Sponsors: Merck Sharp& Dohme LLC; PPD, Part of Thermo Fisher Scientific Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 25, 2023 Category: Research Source Type: clinical trials
MK-2870 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008)
Conditions: Non-small Cell Lung Cancer; Solid Tumors; Programmed Cell Death-1 (PD1, PD-1); Programmed Cell Death 1 Ligand 1(PDL1, PD-L1); Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2) Interventions: Biological: MK-2870; Biological: Pembrolizumab; Drug: Carboplatin Sponsors: Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 22, 2023 Category: Research Source Type: clinical trials
Safety and Pharmacokinetic Study of Oral MK-8527 QM in Participants at Low-Risk for HIV-1 Infection (MK-8527-007)
Conditions: HIV; HIV Pre-exposure Prophylaxis Interventions: Drug: MK-8527; Drug: Placebo to MK-8527 Sponsors: Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
T-Cell Repertoire Sequencing: Assessing Pembrolizumab Efficacy in Advanced Non-small Lung Cancer
Conditions: Non-small Cell Lung Cancer Metastatic Sponsors: Ari Raphael; Bar-Ilan University, Israel; Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Merck Presents New Analyses Supporting the Promising Potential of Sotatercept, its Investigational Medicine for Adults with Pulmonary Arterial Hypertension (PAH)
RAHWAY, N.J.--(BUSINESS WIRE) September 11, 2023 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new analyses from studies of sotatercept, Merck’s novel investigational activin signaling inhibitor... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - September 11, 2023 Category: Pharmaceuticals Source Type: clinical trials
Heart Failure Polypill at a Safety Net Hospital
Conditions: Heart Failure With Reduced Ejection Fraction; HIV Infections Interventions: Drug: Heart failure polypill; Drug: Control Rx Sponsors: University of California, San Francisco; UCSF CAPS-HIV Innovative Grant; UCSF CFAR-ARI HIV Boost Award; ACC/ABC Merck Research Fellowship Award (support for Dr. DeJong) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 8, 2023 Category: Research Source Type: clinical trials
